A 58-year-old man with stage III colorectal cancer (T3N1M0) of the rectum undergoes total mesorectal excision (TME) with curative intent. Regarding the surgical principles and adjuvant therapy in rectal cancer, all of the following are correct EXCEPT:

Explanation

## Analysis of Rectal Cancer Surgical Management ### Correct Statements (Options 0, 1, 3) **Key Point:** Negative circumferential resection margin (CRM) of >1 mm is the gold standard. A positive or close CRM (<1 mm) is an independent predictor of local recurrence and poor prognosis [cite:AJCC Cancer Staging Manual 8e]. **High-Yield:** Neoadjuvant chemoradiotherapy (NCRT) followed by TME is the standard of care for stage II–III rectal cancers. Multiple randomized trials (German CAO/ARO/AIO-94, EORTC 22921) demonstrate improved local control and overall survival compared to surgery alone or adjuvant therapy [cite:Harrison 21e Ch 297]. **Clinical Pearl:** Adjuvant chemotherapy (5-FU/capecitabine ± oxaliplatin) is standard for stage III colorectal cancer to reduce distant recurrence and improve survival [cite:NCCN Guidelines Colorectal Cancer 2023]. ### Incorrect Statement (Option 2) — THE ANSWER **Warning:** This is a common misconception. The choice between APR and AR depends on **tumor location and distance from the anal verge**, NOT a blanket rule for all mid-rectal tumors. | Tumor Location | Sphincter Involvement | Preferred Approach | |---|---|---| | **Upper rectum** (>10 cm from AV) | No | Anterior resection (AR) | | **Mid rectum** (5–10 cm from AV) | **No** | **Anterior resection (AR)** | | **Mid rectum** (5–10 cm from AV) | **Yes** | **APR** | | **Lower rectum** (<5 cm from AV) | Any | APR or ultra-low AR with coloanal anastomosis | **Key Point:** APR is reserved for tumors with **sphincter involvement or <5 cm from the anal verge**. For mid-rectal tumors **without sphincter involvement**, AR with adequate distal margin (≥2 cm) is the standard and preserves continence [cite:Sabiston Textbook of Surgery 21e Ch 52]. ## Summary Option 2 incorrectly generalizes APR to all mid-rectal tumors. The actual decision is individualized based on tumor height, sphincter involvement, and ability to achieve adequate distal margin with sphincter preservation.